An Early Single-Center Case Series Experience With a Recently Introduced Formulation of Inhaled Treprostinil (Yutrepia)
Abstract
Background: Treprostinil inhalation powder produced using PRINT technology (LIQ861; delivered via the RS00 Model 8 dry powder inhaler; Yutrepia) is an FDA-approved inhaled treprostinil therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Evidence from the INSPIRE phase 3 open-label study supported long-term safety and tolerability; however, real-world implementation data remain limited.
Methods: We conducted a retrospective, single-center observational case series of consecutive patients initiated on Yutrepia in routine clinical practice between June and December 2025. Our cohort included group 1, group 3, and mixed group 1 and 3 treated at our Pulmonary Hypertension Center of Excellence. The primary objective of this study was to evaluate the real-world safety and tolerability of Yutrepia, with particular attention to airway-related adverse events (AEs), dose modification, and treatment discontinuation in routine clinical practice. Secondary outcomes included initial and maintenance doses achieved. Additional AEs recorded include dizziness, headache, nausea, hypotension, hypertension, tachycardia, fatigue, and hypoxemia. All data were calculated using a Wilson 95% confidence interval (CI) given the small sample size.
Results: Twenty-two patients were included (mean age: 66.4 ± 13.8 years; 16 (72.7%) female patients). PH etiology was group 1 in 13 of 22 patients (59.1%), group 3 in 3 of 22 (13.6%),…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 22 participants or records.
Read the paper
Related studies
- Protective effects of tadalafil and N-acetyl cysteine therapy on cisplatin-induced testicular toxicity
- The Use of Generative AI for Scientific Literature Searches for Systematic Reviews: ChatGPT and Microsoft Bing AI Performance Evaluation
- Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons
- Ozone-modified properties of pumpkin seed oil as anti-H. pylori, anticancer, anti-diabetic and anti-obesity agent
- Effectiveness of Low-Intensity Extracorporeal Shock Wave Therapy in Erectile Dysfunction: An Analysis of Sexual Function and Penile Hardness at Erection: An Umbrella Review
- Molecular Docking of Silymarin as a Ligand for Aromatase Enzyme and HIV-1 Reverse Transcriptase Using Molegro Virtual Docker
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.